Skip to content
CancerIndex

Loading the knowledge graph…

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC — knowledge graph · CancerIndex